(NASDAQ: EXEL) Exelixis's forecast annual revenue growth rate of 10.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.45%.
Exelixis's revenue in 2026 is $2,435,920,000.On average, 22 Wall Street analysts forecast EXEL's revenue for 2026 to be $655,630,357,032, with the lowest EXEL revenue forecast at $615,985,286,312, and the highest EXEL revenue forecast at $689,824,230,528. On average, 21 Wall Street analysts forecast EXEL's revenue for 2027 to be $738,637,223,852, with the lowest EXEL revenue forecast at $588,729,300,192, and the highest EXEL revenue forecast at $830,068,668,200.
In 2028, EXEL is forecast to generate $816,440,675,140 in revenue, with the lowest revenue forecast at $585,260,356,504 and the highest revenue forecast at $950,738,352,204.